FDA Accepts NDA and Grants Priority Review for Takeda's Narcolepsy Drug Oveporexton
TAK sits 38% above its 52-week low of $12.99.
Summary
Takeda announced the FDA accepted its New Drug Application and granted Priority Review for oveporexton (TAK-861), a potential first-in-class treatment for Narcolepsy Type 1, with a PDUFA date set for Q3 this calendar year.
Key Events · Product Development and Regulatory · TAK
-
NDA Acceptance & Priority Review
The U.S. FDA accepted the New Drug Application (NDA) for oveporexton (TAK-861) for Narcolepsy Type 1 (NT1) and granted it Priority Review.
-
Potential First-in-Class Therapy
Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency in NT1, representing a potential first-in-class treatment.
-
PDUFA Target Action Date Set
The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date in the third quarter of this calendar year, indicating a potential approval decision.
-
Supported by Phase 3 Data
The NDA is supported by positive data from global Phase 3 studies (FirstLight and RadiantLight) demonstrating statistically significant and clinically meaningful improvements across various NT1 symptoms.
Analysis · TAK · Life Sciences
This filing signals a significant advancement in Takeda's neuroscience pipeline, bringing its potential first-in-class narcolepsy treatment, oveporexton, closer to market. The FDA's Priority Review designation underscores the drug's potential to address a high unmet medical need for patients with Narcolepsy Type 1, a chronic neurological disorder. While the filing notes no immediate impact on the current fiscal year's forecast, the long-term commercial potential of a novel therapy in this space could be substantial for Takeda. Investors should monitor the PDUFA target action date in Q3 for potential approval.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TAK was trading at $17.98 on NYSE in the Life Sciences sector, with a market capitalization of approximately $55.9B. The 52-week trading range was $12.99 to $17.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.